Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Alterity Therapeutics Ltd

ATHE
Current price
4.62 USD +0.17 USD (+3.82%)
Last closed 4.25 USD
ISIN US02155X1063
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 23 376 276 USD
Yield for 12 month +126.68 %
1Y
3Y
5Y
10Y
15Y
ATHE
21.11.2021 - 28.11.2021

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.00 USD

P/E ratio

Dividend Yield

Current Year

+2 549 717 USD

Last Year

+2 484 407 USD

Current Quarter

+1 343 953 USD

Last Quarter

+438 169 USD

Current Year

+2 413 769 USD

Last Year

+2 303 569 USD

Current Quarter

+1 269 519 USD

Last Quarter

+413 902 USD

Key Figures ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 571 604 USD
Operating Margin TTM -612.91 %
PE Ratio
Return On Assets TTM -52.66 %
PEG Ratio
Return On Equity TTM -104.47 %
Wall Street Target Price 8.00 USD
Revenue TTM 4 019 285 USD
Book Value 0.0030 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 38.40 %
Dividend Yield
Gross Profit TTM 3 631 266 USD
Earnings per share -4.05 USD
Diluted Eps TTM -4.05 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATHE

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 09.01.2023
Dividend Date

Stock Valuation ATHE

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 113.99
Price Sales TTM 5.82
Enterprise Value EBITDA 0.75
Price Book MRQ 2.39

Financials ATHE

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATHE

For 52 weeks

1.00 USD 3.19 USD
50 Day MA 1.37 USD
Shares Short Prior Month 3 679
200 Day MA 1.65 USD
Short Ratio 0.040
Shares Short 1 953
Short Percent 0.020 %